UNSPSC 51314324: Brompheniramine/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314324 Brompheniramine/phenylephrine/phenylpropanolamine is a Commodity code that in recent state and local procurement activity covers pharmaceutical products including naloxone, multi-source generic medications, and over-the-counter compounds supplied through established distribution channels to public health and human services agencies. The solicitations posted under this code show state and local governments procuring naloxone and drug deactivation systems for community health initiatives, generic multi-source pharmaceuticals through cooperative purchasing alliances serving multiple states, and exploratory contracting for direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state human services commissions (Texas HHS), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) that aggregate demand across member states and local jurisdictions. Vendors respond to IFBs, RFPs, and RFIs with detailed product specifications, pricing models, and compliance certifications covering FDA requirements, Good Manufacturing Practices, and Drug Supply Chain Security Act adherence.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, on a fixed-fee basis with an initial two-year term and one-year renewal option. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with awards effective July 1, 2026, pricing weighted at 75 percent, and a two-year initial contract term with optional extensions. The Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered market intelligence on direct-to-manufacturer prescription fulfillment capabilities to inform future formal solicitations. Vendors must typically maintain substantial insurance coverage including commercial general liability and professional liability, comply with E-Verify employment verification, and supply products with minimum shelf-life requirements and expiration dates at least one year from manufacture.